Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Cullinan Therapeutics, Inc.

In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on Cullinan Management, with a price target of $30.00. Accordin...

Morgan Stanley Keeps Their Buy Rating on Cullinan Management (CGEM)

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Cullinan Management today and set a price target of $28.00. According to TipRa...

Cullinan Management (CGEM) Receives a Rating Update from a Top Analyst

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mesoblast Limited (MEOBF), Cullinan Management (CGEM...

Analysts Are Bullish on These Healthcare Stocks: Mesoblast Limited (MEOBF), Cullinan Management (CGEM)

In a report released today, Robert Driscoll from Wedbush reiterated a Buy rating on Cullinan Management, with a price target of $37.00. Driscoll co...

Wedbush Sticks to Their Buy Rating for Cullinan Management (CGEM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kiniksa Pharmaceuticals (KNSA) and Cullinan Manageme...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CGEM	$20.94	+1.70%	206.32K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CGEM	$20.94	+1.7%	206.32K
3
4
5
6

CGEM

Get Cullinan Therapeutics, Inc. Data in Excel

Get Cullinan Therapeutics, Inc. Data in Excel